A novel immunomodulator, FTY720, prevents development of experimental autoimmune myasthenia gravis in C57BL/6 mice.
Prophylactic oral administration of a novel immunomodulator (immunosuppressant), FTY720 (1 mg/kg, three times a week), completely prevented the development of experimental autoimmune myasthenia gravis (EAMG) in C57BL/6 mice. EAMG has been used as an animal model for human myasthenia gravis, and was established by immunizing the mice with acetylcholine receptor (AChR) from Torpedo californica. FTY720 also suppressed the production of both anti-Torpedo californica AChR antibody and anti-mouse AChR autoantibody by the mice, which were observed in mice in which EAMG had become established. These results strongly suggest that FTY720 is a promising candidate for treatment of human myasthenia gravis.
Kohno
Takeyuki
T
Department of Environmental Health Sciences, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan. kohno@pharm.setsunan.ac.jp
Tsuji
Takumi
T
Hirayama
Kaori
K
Iwatsuki
Rumi
R
Hirose
Michitaka
M
Watabe
Kazuhito
K
Yoshikawa
Hiroaki
H
Kohno
Tomoko
T
Matsumoto
Akiko
A
Fujita
Tetsuro
T
Hayashi
Masatoshi
M
D000818:Animals; D004353:Drug Evaluation, Preclinical; D005260:Female; D000068876:Fingolimod Hydrochloride; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D020720:Myasthenia Gravis, Autoimmune, Experimental / Q000517:prevention & control*; D011409:Propylene Glycols / Q000494:pharmacology*; D013047:Specific Pathogen-Free Organisms; D013110:Sphingosine / Q000031:analogs & derivatives; D013997:Time Factors
D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine